Cargando…
Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18–64 years
Since the authorization of the Moderna mRNA COVID-19 vaccine, real-world evidence has indicated its effectiveness in preventing COVID-19 cases. However, increased cases of mRNA vaccine-associated myocarditis/pericarditis have been reported, predominantly in young adults and adolescents. The Food and...
Autores principales: | Yogurtcu, Osman N., Funk, Patrick R., Forshee, Richard A., Anderson, Steven A., Marks, Peter W., Yang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234830/ https://www.ncbi.nlm.nih.gov/pubmed/37324525 http://dx.doi.org/10.1016/j.jvacx.2023.100325 |
Ejemplares similares
-
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16–29 years
por: Funk, Patrick R., et al.
Publicado: (2022) -
Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022) -
A 17-year-old male with acute myocarditis following mRNA-1273 vaccination in Japan
por: Iwamuro, Ayumi, et al.
Publicado: (2022) -
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
por: Wu, Kai, et al.
Publicado: (2021) -
Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
por: Desai, Amar D, et al.
Publicado: (2022)